论文部分内容阅读
即将在2015年美国心脏病学会科学年会上公布的一项研究显示,房颤患者服用地高辛的全因死亡风险较未服用者高27%,心源性死亡风险高21%;而房颤合并肾衰的患者服用地高辛的风险更是比相似病情下、未服用者的死亡风险增加60%~70%。使用地高辛以前就曾被认为与房颤患者死亡危险增加有关,美国约有560万房颤患者,约20%的房颤患者在接受地高辛治疗。主要研究者、维克森林大学医学院WaqasQ ureshi博士指出,该结果是在对19项研究(1960-2014年)、超过50万患者做出分析后
A study published in 2015 at the annual meeting of the American College of Cardiology Science suggests that all-cause death from digoxin in patients with atrial fibrillation is 27% more likely than non-users and 21% higher risk of cardiac death; Treating patients with tremor and renal failure is associated with a 60% to 70% increased risk of dying of digoxin compared with similar conditions. Digoxin was previously thought to be associated with an increased risk of death from AF in about 5.6 million AF patients in the United States and about 20% of AF patients receiving digoxin therapy in the United States. Principal Investigator Waqas Qüreshi, MD, of Wake Forest University School of Medicine, said the results were analyzed in more than 500,000 patients from 19 studies (1960-2014)